
KalVista Pharmaceuticals is a public pharmaceutical company which has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
In May 2021 Occam placed Paul Audhya, MD as its CMO. Audhya has over 20 years of clinical development and global medical affairs leadership experience. He previously served as Senior Vice President, Global Medical Affairs at Arena Pharmaceuticals. Prior to Arena, Dr. Audhya held positions of increasing responsibility across all stages of drug development at Vertex Pharmaceuticals, Hospira, Reata Pharmaceuticals, Abbott Labs, Amgen, Bristol Myers Squibb and Janssen.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.